Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

zirconium Zr 89-DFO-vandortuzumab vedotin

A radioimmunoconjugate composed of the radioisotope zirconium Zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1) that can potentially be used as a prostate cancer tracer during positron emission tomography (PET). Upon administration of zirconium Zr 89-DFO-vandortuzumab vedotin, the antibody moiety DFO-vandortuzumab vedotin binds to STEAP1 on prostate cancer cells. In turn, Zr 89 allows for the visualization of those cells using PET. STEAP1, a six-transmembrane domain protein, is overexpressed on the surface of prostate cancer cells.
Synonym:89Zr-DFO-MSTP2109A
89Zr-DFO-vandortuzumab vedotin
zirconium Zr 89 DFO-MSTP2109A
Search NCI's Drug Dictionary